Skip to main content
. 2017 Mar 12;2:47–53. doi: 10.1016/j.ibror.2017.03.001

Fig. 5.

Fig. 5

ATSM treatment did not delay onset (A), improve survival (B), or affect overall neurological disease progression (D), despite attaining meaningful plasma and spinal cord exposure levels (C).